Competition Commission Complaint

All materials on this page that have been written and produced by TAC may be reproduced and distributed at no charge and without TAC's permission, so long as the original writers are acknowledged. If you choose to modify the original documents, it must be clearly indicated what your additions are and the original authors must still be acknowledged. Please note, however, that some documents have not been produced by TAC and this notice does not apply to them.

Competition Commission Complaint Against GlaxoSmithKline and Boehringer Ingelheim

16 October 2003

The Competition Commission has announced that they have decided to refer the complaint to the Competition Tribunal, saying that GSK and BI have abused their dominant positions in the market. This is an updated Q&A on drug patents, pricing and related activism, which should be read with the earlier Q&A.
New Q&A (html) - 27 October 2003
Old Q&A (pdf) - 30 October 2002

August 2003

The Aids Law Project has produced an elegant outline (external link, multiple pdfs) of the Competition Commission Complaint.

Documents from 2002

Advertisement (jpg) that appeared in Business Day, Oct/Nov 2002

The main complaint (Word doc) against GlaxoSmithKline and Boehringer Ingelheim.

Statement by TAC (Text Document)

Statement by Action for Southern Africa on the complaint (Word doc)

Council for Medical Schemes Submission to the Commission (Word doc)